Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer.

ABSTRACT:

Background

Young women (≤40 years at diagnosis) with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) represent a high-risk group with distinct biological features. Conventional biomarkers, such as Ki67 and immunohistochemistry (IHC)-based subtypes, are not validated in this population. This study assessed the prognostic value of clinical and genomic biomarkers and explored age-related clinicopathological and gene expression differences.

Patients and methods

A retrospective cohort of 658 patients with ER-positive, HER2-negative EBC who underwent genomic risk testing between 2015 and 2023 at a single institution was analyzed. Patients were stratified by age at diagnosis: ≤40 years (n = 81), 41-50 years (n = 23

SUBMITTER: Walbaum B 

PROVIDER: S-EPMC12495081 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature